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ABSTRACT 
 
The objective of this study was to determine the effects of a structured weight loss 
program that included hypocaloric diet, exercise and dietary supplementation, on weight loss, 
metabolic syndrome risk factors and antioxidant levels in healthy overweight and obese females.  
Thirty-seven healthy overweight and obese women (BMI 29.5 ± 2.3 kg/m2, 41.1 ± 7.1 
yrs) participated in this study.  The subjects were randomized into one of two groups: an 
exercise, hypocaloric diet and antioxidant supplement (LifePak®; LSANT group, n=20) or an 
exercise, hypocaloric diet and appetite suppression supplement (HTP Complex® and TēGreen®; 
LSAS group, n=17).  
A significant weight loss occurred in both groups after 12 weeks (LSANT: -2.8 ± 2.8 kg 
and LSAS: -4.3 ± 2.7 kg, p<0.001).  Body fat mass, percent body fat, and waist circumference 
significantly improved in both groups (p<0.05).  No significant difference was found between 
the groups for weight loss (p>0.05).  However, a significant difference was found between the 
groups for body fat mass (LSANT: -1.8 ± 2.6 kg; LSAS: -3.4 ± 2.4 kg, p ≤ 0.05).  Glucose, 
insulin and insulin resistance (HOMA-IR) were significantly decreased in the LSAS group 
(glucose: -5.0 ± 6.8 mg/dl, p=0.008; insulin: -2.6 ± 3.8 uIU/dl, p=0.013; and HOMA-IR: -0.7 ± 
1.0, p=0.012) but not in the LSANT group (p>0.05).  There were no significant differences 
(p>0.05) observed within or between the groups for cholesterol, triglycerides or LDL-c.  HDL-c 
decreased significantly in the LSANT group (-2.9 ± 5.3 mg/dl, p=0.024) but not in the LSAS 
group (p>0.05).  Skin carotenoid scores (SCS) increased significantly within the LSANT group 
(LSANT: 10950 ± 8395 SCS, p<0.001) but not the LSAS group (p>0.05). 
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Lifestyle intervention that involves a structured hypocaloric diet and increased physical 
activity results in weight loss and improvements in body composition.  However, 
supplementation with an appetite suppressant (HTP Complex®) did not enhance weight loss 
beyond what was achieved with a structured lifestyle intervention.  Antioxidant supplementation 
may be of benefit during a weight loss program that incorporates physical activity and a low 
energy diet.  
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INTRODUCTION 
 
The prevalence and incidence of overweight and obesity continues to rise.  Data from 
NHANES III 2003-2004 indicate that over 97 million Americans or an estimated 66% of adults 
nineteen years and older have a body mass index (BMI) greater than 25 kg/m2 (Ogden et al., 
2006).  Children are showing similar trends with the incidence of childhood obesity having 
tripled (5% to 15%) over the past 30 years (Hedley et al., 2004).  This trend in childhood obesity 
rates, coupled with the adult obesity epidemic, will undoubtedly have enormous impact on future 
health care economics and practices.  Furthermore, life expectancy is anticipated to be lower in 
young obese individuals and mortality rates higher in adults with higher BMI when compared to 
their counterparts with normal BMI (Fontaine, Redden, Wang, Westfall, & Allison, 2003; 
Olshansky et al., 2005).   
It is well accepted that obesity and its co-morbidities present an enormous public health 
challenge.  Prospective cohort studies as well as national surveys show that obese are at 
increased risk for hypertension, stroke, diabetes, cardiovascular disease, arthritis, some forms of 
cancer, and disability. ("Clinical Guidelines on the Identification, Evaluation, and Treatment of 
Overweight and Obesity in Adults--The Evidence Report. National Institutes of Health," 1998; 
Mokdad et al., 2003; Must et al., 1999).  In addition, obese individuals are more likely to exhibit 
a cluster of risk factors commonly known as the metabolic syndrome.  These risk factors include 
insulin resistance, increased levels of central adiposity, low levels of high density lipoprotein 
cholesterol, elevated triglycerides, impaired fasting glucose, and hypertension.  The clustering of 
these risk factors has been shown to enhance the likelihood of developing cardiovascular disease 
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(CVD) (Isomaa et al., 2001; Lakka et al., 2002; Wilson, Kannel, Silbershatz, & D'Agostino, 
1999).   
Obesity and obesity related metabolic and CV abnormalities have been linked to, and 
may be partially the result of high oxidative stress levels (Bartsch & Nair, 2006; Kaneto et al., 
2007; Vaziri, 2004; R. Wolfram, Oguogho, Palumbo, & Sinzinger, 2005).  Oxidative stress, the 
result of chronically elevated levels of highly reactive molecular species (chiefly oxygen and 
nitrogen) has been shown to cause cellular injury and tissue damage, especially in the presence 
of low cellular antioxidant levels.  Of particular importance, BMI and fat accumulation have 
been shown to correlate with markers of systemic oxidative stress (Furukawa et al., 2004; 
Keaney et al., 2003).  Several physiological mechanisms have been proposed that link oxidative 
stress with adiposity.  In the obese, increased lipid peroxidation, protein carbonylation, and 
oxidative damage to amino acids results in increased free radical production and oxidative stress 
(Dandona et al., 2001).  Furthermore, increases in adipose tissue-specific oxidative stress may 
result in increases in the oxidative catabolism of lipid soluble nutrients.  Dandona et al., found 
that many of the factors associated with increased oxidative stress in obese subjects fell 
significantly (>50%) with dietary restriction and weight loss.  These data suggest that reducing 
oxidative stress through weight loss, caloric restriction and consuming diets rich in antioxidants 
may potentially further reduce the morbidity and mortality associated with obesity.  
Several studies have shown that weight loss can be an effective means to reduce CV and 
metabolic abnormalities associated with excess adiposity (Yamaoka & Tango, 2005).  For 
example, results from the U.S. Diabetes Prevention Program (DPP) showed that a diet and 
exercise program resulting in a 5-7% weight loss reduced diabetes by 58% (Knowler et al., 
2002).  The Finnish Diabetes Prevention Study (FDPS) found that diet and exercise in 
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overweight men and women with impaired glucose tolerance resulted in an average weight loss 
of 7 pounds or less than 5% of body weight after 4 years (Lindstrom et al., 2006).  However, the 
risk for diabetes was reduced by 58% which was directly associated with changes in lifestyle.  
Reducing adiposity has been shown to decrease the risk for diabetes and cardiovascular disease 
in addition to improving blood pressure, triglyceride, total cholesterol, LDL-c, HDL-c, and 
glucose levels (Dansinger, Gleason, Griffith, Selker, & Schaefer, 2005; Goldstein, 1992; 
Meckling, O'Sullivan, & Saari, 2004; Obarzanek et al., 2001; Pereira, Swain, Goldfine, Rifai, & 
Ludwig, 2004).  Besides lifestyle, therapeutic approaches commonly used for weight loss include 
pharmacotherapy, surgery, behavioral therapy, and other interventions (acupuncture, herbal 
remedies, supplements, and hypnosis).  In a select population, pharmacotherapy and surgery can 
be an effective means to weight loss.  Improved surgical techniques (bariatric surgery) and the 
development of new long term drug therapies (sibutramine and orlistat) have made these options 
more readily available.  However, side effects and cost continue to be significant barriers to their 
widespread use.  Although significant advances have been made towards understanding the 
pathophysiology of obesity, successful long term therapeutic strategies to reduce or prevent the 
epidemic have proven to be more challenging.   
It is well accepted that lifestyle intervention is a suitable therapeutic choice for reducing 
adiposity.  Weight loss due to caloric restriction or regular exercise alone is generally not 
maintained.  A comprehensive program that combines these approaches results in weight loss 
that is maintained over time, in addition to reducing visceral fat and improving cardiorespiratory 
fitness.  Furthermore, increasing energy expenditure through regular physical activity and 
monitoring caloric intake provides for maintenance of the weight loss.  Numerous studies have 
shown that lifestyle modification may be an effective strategy for weight loss ("Clinical 
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Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in 
Adults--The Evidence Report. National Institutes of Health," 1998).  As noted previously, the 
Finnish DPS and the U.S. DPP showed that lifestyle intervention (diet and exercise) was more 
effective than other treatment modalities in reducing the risk of diabetes.  Improvements in blood 
pressure, high sensitive C-reactive protein, insulin sensitivity and endothelial function have also 
been demonstrated (Aronson et al., 2004; Garrow & Summerbell, 1995; Hambrecht et al., 2000; 
Janssen, Fortier, Hudson, & Ross, 2002; Okita et al., 2004; Selvin, Paynter, & Erlinger, 2007).  
Furthermore, many of the type II diabetes and cardiovascular disease cases due to excess 
adiposity may be prevented or reversed with simple lifestyle changes such as adopting a healthy 
low calorie balanced diet and increasing physical activity (Tuomilehto et al., 2001; Volek, 
Vanheest, & Forsythe, 2005).  
Over the past decades eating habits and food choices have changed dramatically.  
Significant changes in portion size and the type of foods consumed (energy dense versus nutrient 
dense) have occurred.  Lean individuals tend to consume nutrient dense diets that include foods 
such as fruits and vegetables that provide substantial amounts of vitamins, minerals and 
phytochemicals (Rolls, Ello-Martin, & Tohill, 2004).  Energy dense diets on the other hand, lack 
essential nutrients necessary for good health and are typically low in fiber and high in fat and 
sugar.  Several studies have found an association between energy dense diets and obesity 
(Howarth, Murphy, Wilkens, Hankin, & Kolonel, 2006; Ledikwe et al., 2006).  The recent 
popularization of many hypocaloric diets that offer very low or very high amounts of protein, 
carbohydrates, or fat tend to be poor in micronutrient content and are often nutritionally 
unbalanced.  However, even well planned hypocaloric diets often fail to meet recommended 
daily allowances for many nutrients. As the intake of macronutrients fall above or below the 
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Acceptable Macronutrient Distribution Range, the risk for chronic diseases increases (Kant, 
2000).  Therefore a diet containing a variety of foods is considered the best approach to ensure 
sufficient intake of all nutrients.  
Fruits and vegetables contain thousands of biologically active phytochemicals and 
antioxidants that interact in a number of ways to prevent disease and promote health. 
Antioxidants work synergistically to sustain elaborate defense systems to prevent or lessen the 
damage caused by oxidative stress.  Furthermore, antioxidants have been shown to enhance 
immune function, increase longevity and prevent many chronic disease states (Fairfield & 
Fletcher, 2002; Tapiero, Townsend, & Tew, 2004).   
Several studies have found an inverse relationship between carotenoid levels (diet and/or 
serum) and BMI (Andersen et al., 2006; Brady, Mares-Perlman, Bowen, & Stacewicz-
Sapuntzakis, 1996; Moor de Burgos, Wartanowicz, & Ziemlanski, 1992).  The decreased 
consumption of dietary antioxidants, in addition to alterations in absorption, distribution, 
metabolism and/or excretion may be responsible for the lower levels of antioxidants found in 
individuals with higher BMI.  Furthermore, because many carotenoids are fat soluble (increased 
storage in adipose tissue) and adipose tissue generates higher levels of oxidative stress, the 
circulating (serum) levels of antioxidants may be lower in overweight and obese individuals.  
Results from our lab and by others found a strong inverse relationship to exist between indices of 
adiposity and antioxidant levels (Fiutem J, 2004; Kimmons, Blanck, Tohill, Zhang, & Khan, 
2006).  
The measurement of antioxidants in serum, tissue and urine is cost and time prohibitive 
when applying conventional methods.  New technology however, has allowed for the 
measurement of antioxidants to be quick, affordable and noninvasive.  Carotenoids, which are fat 
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soluble antioxidants, can now be measured in the stratum corneum layer of the skin using Raman 
Spectroscopy (Ermakov, Sharifzadeh, Ermakova, & Gellermann, 2005).  Raman Spectroscopy 
uses a powerful laser that detects characteristic vibrations/rotational energy levels of a molecule 
and has been validated and shown to be as effective as blood and tissue sampling (Ermakov et 
al., 2005; Rerksuppaphol & Rerksuppaphol, 2006; Stahl et al., 1998).  Recent work in our lab 
using Raman Spectroscopy demonstrated that overweight and obese individuals on a well 
designed program of mild caloric restriction and exercise significantly reduced skin catotenoid 
scores and presumably overall antioxidant status despite the fact that dietary carotenoid 
consumption did not change (Zukley L, 2004).  Therefore, dietary supplementation may be 
necessary in order to maintain acceptable levels of micronutrients, especially during times of 
caloric restriction.  
Food intake (eating) is determined by complex interactions between biological 
mechanisms of appetite control and responses to challenges from the physical environment 
(Figure 1).  
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Figure 1. Factors Regulating Appetite, Energy and Metabolism 
 
 
A number of hormones participate in appetite control and are currently under investigation 
(leptin and ghrelin).  Serotonin is a neurotransmitter that controls appetite.  Taken orally, 
serotonin cannot pass the blood brain barrier but relies on the amino acid tryptophan and its 
metabolite 5-hydroxytryptophan (5-HTP).  Overweight and obese individuals have been found to 
have lower blood levels of serotonin (Ceci et al., 1989).  In studies involving obese individuals 
taking daily dietary supplements containing 5-HTP, significant weight loss was observed 
(Cangiano et al., 1992; Cangiano et al., 1998; Ceci et al., 1989).  Recent research has also 
investigated the role of plant ingredients in weight control.  Currently under investigation is 
green tea.  Catechins found in green tea may activate thermogenesis and/or fat oxidation through 
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the sympathetic nervous system generating favorable changes in body composition (Dulloo et al., 
1999; Dulloo, Seydoux, Girardier, Chantre, & Vandermander, 2000).   
Furthermore, green tea contains polyphenols which have strong antioxidant effects.  
Numerous studies have reported significant increases in plasma antioxidant capacity and 
reductions in the biomarkers for oxidative stress after one to four weeks of green tea 
consumption (Higdon & Frei, 2003; Rietveld & Wiseman, 2003).  Research suggests that adding 
green tea to a balanced controlled diet may improve overall antioxidant status and protect against 
oxidative damage.  Therefore, combining a weight loss program involving hypocaloric diet and 
exercise with a dietary supplement may help individuals maintain or improve their antioxidant 
status in addition to promoting weight loss.  
Given the health promoting effects of weight loss and the importance of antioxidants in 
maintaining health, the purpose of this study was three-fold: 1) To determine the effect of a 
lifestyle modification program (diet and exercise) on weight and risk factors for the metabolic 
syndrome and CVD; 2) To determine the effect of a dietary appetite control supplement on 
weight; and 3) To determine the effect of a dietary antioxidant supplement and weight loss on 
skin antioxidant levels.    
 8
METHODS 
 
Study Design 
 
This study was a single-site, randomized, controlled 12-week study.  Subjects were randomized 
into one of two groups: an exercise, hypocaloric diet and antioxidant supplement (LifePak®; 
LSANT group) or an exercise, hypocaloric diet and appetite suppression supplement (HTP 
Complex® and TēGreen®; LSAS group).  The protocol was approved by the University of 
Central Florida Institutional Review Board, Orlando, Florida and written informed consent was 
obtained on all subjects.  
Subjects 
 
One hundred and twenty-three healthy, sedentary, overweight males and females with a BMI of 
27-35 kg/m2 and 25 to 50 years old were enrolled.  Characteristics of all subjects at baseline are 
shown in Table 1.  
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Table 1. 
Baseline Characteristics of All Subjects Enrolled  
                                                                                    
                                                                     All                                                                                
Characteristics                                         (N=123)                                                                     
 
Age (yr)                         40.3 ± 8.2                   
 
Height (cm)                        163.6 ± 7.4                    
   
Weight (kg)                        80.7 ± 11.0                    
                                                                 
BMI (kg/m2)                                   30.92 ± 2.5                                
 
Skin carotenoid (SCS)                      19246 ± 6184     
          
Oxidative stress (U.Carr)                      326.4 ± 82.7                
   
Note.  BMI, body mass index.  SCS, skin carotenoid score 
 
 
The subjects (N=123) enrolled in the study were part of a major interventional study examining 
the effects of a structured weight loss program on risk factors for metabolic syndrome and 
oxidative stress.  A sub-cohort (n=37) was used in the present investigation.  Based on the 
premise that gender, cigarette smoking, and birth control are known to adversely affect oxidative 
stress and antioxidant levels, female subjects that did not smoke and were not on birth control 
were included (Alberg, 2002; Berg, Kohlmeier, & Brenner, 1997).  Therefore, analyses were 
conducted and reported on 37 Caucasian females that met these criteria and for which complete 
data were available at week 12.  Flow of subjects based on screening and selection criteria is 
depicted in Figure 2.   
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Figure 2. Flow of Subjects Based on Screening and Selected Criteria 
 
 
The subjects responded to newspaper advertisements and fliers in their communities.  Subjects 
were weight stable (± 5 pounds) and sedentary (less than 150 minutes a week of moderate 
intensity physical activity) for at least 30 days prior to enrollment.  A history of cancer, diabetes, 
glucose intolerance, limitations to exercise (orthopedic or cardiac), recent surgery (within 3 
months), diagnosed psychological illness, or previous significant cardiovascular events 
precluded subjects from study participation.  In addition, all vitamin, herbal, or mineral 
supplements that had any known affect on antioxidant levels were discontinued prior to 
screening visit 1.  
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Intervention 
 
Subjects were randomly assigned to an exercise, hypocaloric diet and antioxidant supplement 
(LSANT) group or an exercise, hypocaloric diet and appetite suppression supplement (LSAS) 
group.  See Table 2 for the study procedure chart.   
 
Table 2. 
Study Procedure Chart 
Evaluation 
 
Baseline Week 2 Week 12 
Informed Consent 
 
X   
Anthropometric: 
Weight, Height, BMI calculated, Waist circumference, DXA 
 
X  X 
Blood Analysis:  
Glucose, Insulin, hs-CRP, Lipid panel, Oxidative stress 
 
X  X 
Skin Carotenoid Score  
 
X X X 
Exercise Tolerance Test with VO2max 
 
X  X 
3-Day Food Record 
 
X  X 
Resting Metabolic Rate  
 
X  X 
Evaluate Compliance 
 
X X X 
Dispense Productn 
 
X X  
Note. BMI, body mass index. DXA, dual energy x-ray absorptiometry.  
HS-CRP, high sensitivity C-reactive protein.  
VO2max, maximal oxygen consumption. 
X=All subjects 
n LifePak® or HTP Complex®/Tēgreen®
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Exercise Prescription 
An exercise physiologist instructed subjects on an individualized aerobic exercise program that 
gradually increased in duration, intensity and frequency ("American College of Sports Medicine 
Position Stand. The recommended quantity and quality of exercise for developing and 
maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults," 1998).  
Participants were instructed on how to fill out an exercise diary and then were instructed to 
exercise at 60-80% of their heart rate based on their maximal exercise test (to be described 
below).  Table 3 provides a description of the exercise prescription given to the subjects.  
 
Table 3. 
Exercise Prescription 
Week 1 2 3 4 5 6 7 
Day 1 30 min 30 min 45 min 45 min 45 min 45 min 45 min 
Day 2 30 min 30 min 45 min 45 min 45 min 45 min 45 min 
Day 3 30 min 30 min 45 min 45 min 45 min 45 min 45 min 
HR % 50-60% 50-60% 60-80% 60-80% 60-80% 60-80% 60-80% 
 
Week 8 9 10 11 12 
Day 1 45 min 45 min 45 min 45 min 45 min 
Day 2 45 min 45 min 45 min 45 min 45 min 
Day 3 45 min 45 min 45 min 45 min 45 min 
Day 4 45 min 45 min 45 min 45 min 45 min 
HR % 60-80% 60-80% 60-80% 60-80% 60-80% 
Note.  HR, heart rate 
 
 
Walking was encouraged.  However, any aerobic activity that allowed the participant to exercise 
at 60-80% of their heart rate was acceptable.   
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Nutrition Counseling 
The nutrition plan for the hypocaloric diet in both groups was based on the Exchange Lists for 
Meal Planning from the American Diabetes Association and the American Dietetic Association 
(American Diabetes Association, 2003).  A registered dietitian determined energy intake for each 
subject and a plan was developed that resulted in a 1.0 -1.5 lb (0.5-0.7 kg) weight loss per week.  
This weight loss amount corresponded to a 500 kcal deficit per day for each participant.  Energy 
intake was determined based on their resting metabolic rate (RMR) measured by fasting oxygen 
consumption (MedGem, Healthetech, Golden, CO USA).  Resting metabolic rate was then 
multiplied by the activity factor (1.3) to estimate total energy expenditure and then 500 was 
subtracted to provide the calorie level necessary to achieve this goal.    
  (RMR x 1.3) – 500 kcal=calorie level recommended for weight loss 
All subjects were instructed to consume at least 1000 kcals a day.  Macronutrient content of both 
groups was based on percent of ingested calories and was approximately 55% carbohydrate, 20% 
protein, and 25% fat.  Subjects were provided with and were instructed on following and keeping 
daily calorie specific, nutrition checklists.  The checklists included goals for fruit, vegetable, 
grain, dairy, lean protein sources and water consumption.  
Supplements 
LifePak® or HTP Complex®/Tēgreen® (Pharmanex, Provo, Utah) were dispensed at baseline and 
at week 2.  Refer to Appendix B for dietary supplement information.  Subjects taking LifePak® 
(LSANT group) were instructed to take 1 packet consisting of 4 capsules twice a day with food.  
Those assigned to the LSAS group were instructed to take 2 HTP Complex® capsules and 1 
Tēgreen® capsule three times a day with meals.  A 2-week supply of supplements was given at 
baseline.  An additional 10-weeks supply of supplement was provided at week 2.  Compliance 
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was observed by unused supplement being returned and adverse affects reported as they 
occurred.  In addition, skin carotenoid scores (SCS) were measured at week 2 (SCS would be 
expected to increase above baseline in the LSANT group after 2 weeks of taking the 
supplement).  All subjects were instructed to refrain from taking any additional vitamin, mineral 
or herbal supplements for the duration of the study.  
Physiological Measurements 
 
Anthropometric   
Weight was measured while in a fasting state on a balance beam scale with attached stadiometer 
(Seca, Hanover, MD USA).  Height was measured with shoes off.  Body mass index (BMI) was 
calculated (mass (kg) ÷ height (m2)).  A tape measure with a calibrated spring loaded 6 oz 
tension was used to measure waist circumference (Gulick tape measure).  The average of three 
measurements was used.  The smallest area between the umbilicus and the ziphoid process was 
measured during a normal exhalation.  Body fat mass and fat free mass was determined using 
whole-body dual energy x-ray absorptiometry (DXA), (DPX-MD+, GE Lunar).   
Blood Sampling and Analysis    
A 10-12 hour over night fast preceded each blood draw.  A 3 ml additive free vacutainer tube 
and a 9.5 ml SST gel and clot activator vacutainer tube (Becton Dickinson and Company, 
Franklin Lake NJ, USA) were drawn with a 21g butterfly needle inserted into the antecubital 
fossa of either arm.  Whole blood for serum analyses was coagulated for 30 minutes at room 
temperature (20°C) before centrifugation for 30 minutes.  The SST tube was refrigerated at 4°C 
until analysis completed.  Serum was analyzed for glucose, insulin, high sensitivity C-reactive 
protein, and lipid levels (Cognoscenti, Orlando, FL).  Reactive oxygen metabolites were 
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measured immediately upon collection using a sample of blood from the 3 ml additive free 
vacutainer tube.  The Free Radical Analytical System (FRAS) was utilized (IRAM, Parma Italy 
FRAS-3 version 1.3).  The FRAS system consists of a photometer, a mini-centrifuge and a 
reagent called d-ROMs test Diacron.  The FRAS measures the products of oxidation that the free 
radicals generate in the cell, oxidating lipids, proteins, and amino acids.  These products 
(hydroperoxides) are expelled from the cell, enter the blood flow, are stable and are proportional 
to the number of free radicals that generated them.  The results from the blood test reveal the 
level of oxidative stress which is measured in Carr units.  One Carr unit corresponds to a 
concentration of hydrogen peroxide of 0.08 mg.  Oxidative stress levels are normal at 250 
U.Carr, borderline at 250 to 300 U.Carr, light to strong at over 300 U.Carr, and very strong at 
over 400 U.Carr.  Recent physical activity, smoking, birth control, pathological conditions and 
inflammation increase oxidative stress levels.  
Skin Carotenoids    
Skin carotenoids were measured using the Biophotonic scanner (Pharmanex, Provo, Utah USA).  
Subjects were instructed to place the palm of their right hand in front of the scanners low-energy 
blue light laser for 3 minutes.  Upon completion, the skin carotenoid score (SCS) was reported 
on a lap-top computer screen.  Raman spectroscopy is based on the principal that molecules in 
the body can reflect a different set of colors when stimulated with a light source of a known 
frequency.  This color spectrum is a unique optical fingerprint.  The scanner operates with two 
light-emitting diodes (471.3 nm and 473 nm; blue light).  When either diode hits a carotenoid 
molecule in the hand, a green light (507.8 nm or 509.8 nm) is produced and detected by a 
photomultiplier tube.  The resulting value is the skin carotenoid score (SCS).  Each 1000 units of 
a skin carotenoid score represents approximately 0.04 - 0.06 mcg of carotenoid per milliliter of 
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blood.  The correlation of serum carotenoid concentrations to scanner scores is a linear equation.  
A skin carotenoid score of 25,000 represents the daily recommended intake of 5-6 servings of 
fruits and vegetables a day and/or the use of a dietary supplement containing carotenoids. 
Exercise Tolerance Testing/Maximal Oxygen Consumption (VO2max)    
Subjects were instructed not to eat for at least 3 hours prior to testing and to be dressed for 
exercise.  A brief history and physical examination were obtained by an exercise physiologist or 
registered nurse.  The skin on the chest, abdomen and or back was prepped (hair was shaved if 
required for good skin contact) with alcohol prep pads in order to remove lotions and/or oils for 
lead placement (10 leads, 6 precordial and 4 limb) for continuous electrocardiogram (ECG) 
monitoring during the test.  A supine 12-lead ECG and blood pressure were obtained to rule out 
abnormalities.  Blood pressure was repeated in a standing position.  An explanation on 
procedures and expectations of the test in accordance with the American College of Sports 
Medicine (ACSM) guidelines was given to each subject (Johnson, 2000).  Subjects were further 
instructed to rate their perceived exertion (Borg’s RPE scale, 6-20) every 3 minutes during the 
test and immediately at the end by pointing at a scale provided (Borg, 1998).  Calibrations were 
performed prior to each test on the metabolic cart (PhysioDyne, Quague NY).  Appropriate sized 
head gear, mouth piece, and nose clips were fitted on each subject.  All tests were performed on 
a treadmill (Marquette 2000) using a ramp protocol.  In brief, an exercise physiologist evaluated 
the subject’s capabilities and assigned one of two protocols (walking or athletic/running).  
Regardless of the protocol chosen, ramp speed and grade increased every 30 seconds.  All tests 
included a 2-3 minute warm up and a 5 minute cool down period.  Blood pressure was taken 
every 3 minutes during the test, immediately at recovery and at cool down.  Subjects were 
instructed to continue the test until a maximal test was attained (no change in oxygen uptake 
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despite increasing workload), the operator terminated the test due to participant condition, or the 
participant terminated the test.   
Diet and Nutrient Intake  
Detailed instruction by registered dietitians using visual tools such as food models and common 
household measuring utensils was done in order for participants to accurately complete the 3-day 
food records at baseline and week 12.  Participants were instructed to maintain normal dietary 
habits and record diet during 2 work days and 1 day off.  The diet records were reviewed with 
the participants the following week by the dietitian to ensure accuracy and then entered by a 
trained dietitian into the Nutrient Data System for Research (NDS-R), software (University of 
Minnesota Minneapolis, Minnesota USA).  In addition to the above, nutrient information was 
obtained through food labels, recipes, online resources or NDS support staff.  
Resting Metabolic Rate  
Following a 10-12 hour fast and prior to exercise, direct measure of oxygen consumption was 
measured by indirect calorimetry using the MedGem (Healthetech, Golden, CO USA).  Subjects 
were directed to a quiet room where they sat for 5 minutes prior to starting the test.  Subjects 
were then given a hand held device with a mouthpiece and nose plugs and they were instructed 
to breathe normally and to sit as quietly as possible during the measurement which took 5-10 
minutes.     
Statistical Analyses 
 
Values are presented in the figures and tables as means ± standard deviation.  All analyses were 
conducted at the two-tailed 0.05 α-level.  Paired sample t-tests were used to examine differences 
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over time within the groups.  Independent t-tests were used to compare the delta scores over time 
between the groups.  Significance level was set at p ≤ 0.05.  Statistical analyses was performed 
using SPSS windows software version 11.0 (2001, SPSS Inc). 
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RESULTS 
 
Subjects 
Characteristics of the subjects that completed the study are shown in Table 4. 
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Table 4. 
Characteristics at Baseline for Criteria-Based Subjects that Completed the Study 
                                                                                           
                                                           LSANT                             LSAS                                   pa         
  Characteristics                                 (n=20)                               (n=17)                                                 
 
Age (yr) 42.0 ± 8.1  42.0 ± 5.8  40.0 ± 5.8  0.388   
        
Height (cm)   160.8 ± 5.3  162.3 ± 5.8  0.428  
   
Weight (kg)   75.9 ± 9.0  79.1 ± 9.0  0.298   
                                                                                  
BMI (kg/m2)                29.2 ± 2.3  29.9 ± 2.3  0.385     
 
Systolic blood pressure (mm/Hg) 111.4 ± 13.2            115.4 ± 11.3  0.333    
 
Diastolic blood pressure (mm/Hg)  67.0 ± 18.2                   71.6 ± 11.4  0.369   
    
Cholesterol (mg/dl)                  205.3 ± 40.6                 182.9 ± 28.5  0.065 
 
Triglycerides (mg/dl)                 127.7 ± 66.1                 115.6 ± 60.2  0.569 
 
HDL-c (mg/dl)                          54.1 ± 10.1                   57.3 ± 15.3  0.436 
 
LDL-c (mg/dl)                          125.5 ± 31.9                 105.3 ± 24.7  0.041 
 
Insulin (uIU/dl)                       9.7 ± 5.6                       9.5 ± 5.6  0.930 
 
Glucose (mg/dl)                        91.6 ± 6.0                    94.7 ± 9.5  0.243 
 
HOMA-IR                                        2.2 ± 1.3                      2.3 ± 1.5  0.903 
                                          
Skin carotenoid (SCS)         19850 ± 6115     18882 ± 7381  0.665 
 
Oxidative stress (U.Carr)          310.8 ± 52.3     325.4 ± 79.0  0.507 
     
Note.  BMI, body mass index. HDL-c, high density lipoprotein cholesterol. LDL-c, low density lipoprotein 
cholesterol. HOMA-IR, homeostasis model assessment insulin resistance. 
ap-values for between group differences compared by independent samples t-test 
Treatment group hypocaloric diet, exercise and dietary antioxidant supplement (LSANT) or hypocaloric diet, 
exercise and appetite suppression supplement (LSAS) 
 
 
No differences were observed in body weight at baseline between the two groups (LSANT: 75.9 
± 9.0 kg; LSAS: 79.1 ± 9.0 kg).  Among CV and metabolic risk factors, there were no 
differences at baseline between the groups for glucose, insulin, HOMA-IR, systolic and diastolic 
 21
blood pressure and total cholesterol, HDL-c, and triglycerides.  There was a significant 
difference (p=0.41) at baseline between the groups for LDL-c (LSANT: 125.5 ± 31.9 mg/dl; 
LSAS: 105.3 ± 24.7 mg/dl).  As per the protocol, subjects were instructed to discontinue use of 
dietary or herbal supplements known to increase antioxidant levels at least 3 weeks prior to 
enrollment.  There was no difference in skin carotenoid scores at baseline between the two 
groups (LSANT: 19850 ± 6115 SCS; LSAS: 18882 ± 7381 SCS).  Oxidative stress levels also 
were not significantly different at baseline (LSANT: 310.8 ± 52.3 U.Carr; LSAS: 325.4 ± 79.0 
U.Carr). 
Intervention Effects 
 
Body Weight and Composition
 As shown in Table 5, significant (p≤0.05) within group changes were observed for BMI, body 
weight, fat mass, percent body fat, and waist circumference in both the LSANT and the LSAS 
group following 12 weeks of lifestyle intervention (hypocaloric diet and exercise). 
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Table 5. 
Body Weight and Composition at Baseline and Week 12 
                                                                               
                                                                         LSANT                               LSAS                                                              
Measure                             Study Period          ± s.d. (P-value)a                 ± s.d. (P-value)a                           pb 
                                                                         (n=20)                                (n=17)                                                 
 
BMI (kg/m2)  Baseline  29.2 ± 2.3  29.9 ± 2.3     
   Week 12 28.2 ± 2.1   28.3 ± 2.1 
   Change  -1.0 ± 1.0 (<0.001) -1.6 ± 1.0 (<0.001) 0.089 
Body weight (kg)  Baseline  75.9 ± 9.0  79.1 ± 9.0 
   Week 12 73.2 ± 8.1  74.7 ± 8.6 
   Change  -2.8 ± 2.8 (<0.001) -4.3 ± 2.7 (<0.001) 0.092 
  
Body fat mass (kg) Baseline  34.1 ± 3.9  36.3 ± 6.2   
   Week 12 32.3 ± 3.9  32.8 ± 6.6 
   Change  -1.8 ± 2.6 (0.006)  -3.4 ± 2.4 (<0.001) 0.052 
 
Body fat (%)                       Baseline    46.7 ± 3.0               47.3 ± 4.2 
                                            Week 12   45.7 ± 3.2                       45.2 ± 5.2 
                                            Change       -1.0 ± 2.1 (0.052)              -2.0 ± 2.2 (0.002)       0.138 
 
Body lean mass (kg) Baseline  39.2 ± 5.8  40.2 ± 4.5 
   Week 12 38.3 ± 5.1  39.2 ± 4.0 
    Change  -0.8 ± 1.6 (0.028)  -1.0 ± 1.5 (0.010)  0.808 
 
Waist circumference (cm) Baseline  88.0 ± 9.4  88.1 ± 7.7 
   Week 12 84.7 ± 8.7  84.3 ± 7.1 
   Change  -3.3 ± 2.4 (<0.001) -3.8 ± 2.2 (<0.001) 0.516 
        
Note.  BMI, body mass index 
Treatment group hypocaloric diet, exercise and dietary antioxidant supplement (LSANT) or hypocaloric diet, 
exercise and appetite suppression supplement (LSAS) 
ap-values for within-group change from baseline compared by paired samples t-test 
bp-values for between group mean changes compared by independent samples t-test 
 
 
Average weight loss from baseline to week 12 was -2.8 ± 2.8 kg (3.7%) for the LSANT group 
and -4.3 ± 2.7 kg (5.4%) for the LSAS group.  Significant decreases in lean body mass were 
found in both groups after 12 weeks (LSANT: -0.8 ±1.6 kg, p=0.028; LSAS:-1.0 ± 1.5 kg, 
p=0.010).  A significant mean difference in body fat mass was found between the groups at week 
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12 (p=0.052).  No between group differences in weight were found following 12 weeks of 
dietary supplementation (p=0.092).   
Cardiovascular Fitness and Blood Pressure 
Significant improvements in relative VO2max occurred within the groups (LSANT: 2.2 ± 2.6 
ml/kg/min, p=0.008; LSAS: 2.1 ± 2.4 ml/kg/min, p=0.006) after 12 weeks of increasing physical 
activity (Table 6).  
 
Table 6. 
Blood Pressure and Aerobic Capacity at Baseline and Week 12 
                                                                               
                                                                         LSANT                               LSAS                                                              
Measure                             Study Period          ± s.d. (P-value)a                 ± s.d. (P-value)a                           pb 
                                                                         (n=20)                                (n=17)                                                 
Systolic blood pressure      Baseline    111.4 ± 13.2          115.4 ± 11.3 
(mm/Hg)                             Week 12   107.8 ± 12.3                   112.5 ± 10.0 
                                            Change       -3.6 ± 11.6 (0.183)            -2.9 ± 9.9 (0.237)       0.855 
 
Diastolic blood pressure Baseline  67.0 ±  18.2  71.6 ± 11.4 
(mm/Hg)  Week 12 69.5 ± 12.7  75.3 ± 7.4 
    Change  2.5 ± 15.9 (0.490) 3.6 ± 11.4 (0.208) 0.806 
 
Relative VO2max                  Baseline 23.7 ± 4.9  25.5 ± 6.3 
(ml/kg/min)                Week 12 25.9 ± 4.8  27.6 ± 6.5 
   Change  2.2 ± 2.6 (0.008)  2.1 ± 2.4 (0.006)  0.966 
 
Absolute VO2max                Baseline 1.9 ± 0.4  2.0 ± 0.4 
(L/min)   Week 12 2.0 ± 0.4  2.2 ± 0.4 
   Change  0.1 ± 0.2 (0.154)  0.2 ± 0.3 (0.028)  0.285 
        
Treatment group hypocaloric diet, exercise and dietary antioxidant supplement (LSANT) or hypocaloric diet, 
exercise and appetite suppression supplement (LSAS) 
ap-values for within-group change from baseline compared by paired samples t-test 
bp-values for between group mean changes compared by independent samples t-test 
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Absolute VO2max improved significantly in the LSAS group (0.2 ± 0.3 L/min, p=0.028) but not 
the LSANT group (p>0.05).  Systolic and diastolic blood pressure did not change significantly in 
either group.  There were no between group differences noted for blood pressure or aerobic 
capacity.  
Blood Chemistry 
 As shown in Table 7, there were no significant within group or between group differences found 
in cholesterol, triglycerides, LDL-c, and hs-CRP in either group (p>0.05). 
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Table 7. 
Serum Values at Baseline and Week 12 
                                                                               
                                                                         LSANT                               LSAS                                                         
Measure                             Study Period          ± s.d. (P-value)a                 ± s.d. (P-value)a                            pb 
                                                                         (n=20)                                 (n=17)                                                 
 
Cholesterol (mg/dl) Baseline  205.3 ± 40.6  182.9 ± 28.5     
   Week 12 204.5 ± 45.6   174.8 ± 38.2 
   Change  -0.7 ± 18.3 (0.857) -8.2 ± 22.2 (0.149) 0.273 
Triglycerides (mg/dl) Baseline  127.7 ± 66.1  115.6 ± 60.2 
   Week 12 142.2 ± 76.0  102.3 ± 51.2 
   Change  14.5 ± 46.0 (0.175) -13.3 ± 57.8 (0.357) 0.112 
  
HDL-Cholesterol (mg/dl) Baseline  54.0 ± 10.1  57.3 ± 15.3   
   Week 12 51.1 ± 9.4  54.9 ± 15.6 
   Change  -2.9 ± 5.3 (0.024)  -2.5 ± 9.9 (0.318)  0.867 
 
LDL-Cholesterol (mg/dl) Baseline  125.5 ± 31.9  105.3 ± 24.7 
   Week 12 124.7 ± 35.4  101.8 ± 31.1 
    Change  -0.8 ± 15.3 (0.817) -3.6 ± 19.1 (0.450) 0.625 
 
Glucose (mg/dl)    Baseline  91.7 ± 6.0  94.7 ± 9.5 
   Week 12 91.6 ± 7.4  89.7 ± 10.0 
   Change  -0.05 ± 6.1 (0.971) -5.0 ± 6.8 (0.008)  0.026 
 
Insulin  (uIU/dl)    Baseline  9.74 ± 5.6  9.6 ± 5.6 
   Week 12 8.28 ± 5.7  7.0 ± 3.9 
   Change  -1.4 ± 4.6 (0.175)               -2.6 ± 3.8 (0.013)  0.437 
 
HOMA-IR                  Baseline  2.2 ± 1.3  2.3 ± 1.5 
   Week 12 1.9 ± 1.3  1.6 ± 0.9 
   Change  -0.3 ± 1.1 (0.187)  -0.7 ± 1.0 (0.012)  0.301 
   
hs-CRP (mg/L)                  Baseline       5.6 ± 5.0                        4.5 ± 4.7 
                Week 12      4.9 ± 4.0                        3.7 ± 3.2 
                                           Change                 0.7 ± 3.0 (0.315)      -0.9 ± 2.7 (0.208)               0.841 
 
Note.  HOMA, homeostasis model assessment insulin resistance. hs-CRP. high sensitivity C-reactive protein 
Treatment group hypocaloric diet, exercise and dietary antioxidant supplement (LSANT) or hypocaloric diet, 
exercise and appetite suppression supplement (LSAS) 
ap-values for within-group change from baseline compared by paired samples t-test 
bp-values for between group mean changes compared by independent samples t-test 
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A significant difference in HDL-c was found in the LSANT group but not the LSAS group 
(LSANT: 54.0 ± 10.1 mg/dl to 51.1 ± 9.4 mg/dl, p=0.024; LSAS: 57.3 ± 15.3 mg/dl to 54.9 ± 
15.6 mg/dl, p=0.318).  In the LSAS group, glucose (94.7 ± 9.5 mg/dl to 89.7 ± 10.0, p=0.008), 
insulin (9.6 ± 5.6 uIU/dl to 7.0 ± 3.9 uIU/dl, p=0.013) and insulin resistance (HOMA-IR) (2.3 ± 
1.5 to 1.6 ± 0.9, p=0.012) were significantly decreased but not in the LSANT group (p>0.05).  A 
significant mean difference was found between the groups for glucose (LSANT: -0.05 ± 6.1 
mg/dl; LSAS -5.0 ± 6.8 mg/dl, p=0.026) but not for insulin or for HOMA-IR after 12 weeks 
(p>0.05). 
Skin Carotenoid Score 
There was a significant increase in skin carotenoid scores in the LSANT group (19850 ± 6115 to 
30800 ± 8745 SCS, p<0.001), but not the LSAS group (18882 ± 7381 to 20176 ± 6757 SCS, 
p=0.071) following 12 weeks of dietary supplementation (Table 8). 
 
Table 8. 
Skin Carotenoid Scores at Baseline and Week 12 
                                                                               
                                                                         LSANT                                LSAS                                                             
Measure                             Study Period          ± s.d. (P-value)a                  ± s.d. (P-value)a                             pb 
                                                                         (n=20)                                  (n=17)                                                 
 
Skin carotenoid (SCS) Baseline  19850 ± 6115  18882 ± 7381   
   Week 12 30800 ± 8745  20176 ± 6757 
   Change  10950 ± 8395 (<0.001) 1294 ± 2756 (0.071) <0.001   
Note. SCS, skin carotenoid score 
Treatment group hypocaloric diet, exercise and dietary antioxidant supplement (LSANT) or hypocaloric diet, 
exercise and appetite suppression supplement (LSAS) 
ap-values for within-group change from baseline compared by paired samples t-test 
bp-values for between group mean changes compared by independent samples t-test 
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A significant mean difference was found between the groups after 12 weeks (p<0.001).  
Diet Intake 
Changes in dietary intake are depicted in Table 9. 
 
Table 9. 
Diet Characteristics at Baseline and Week 12 
                                                                               
                                                                         LSANT                                LSAS                                                             
Measure                             Study Period          ± s.d. (P-value)a                  ± s.d. (P-value)a                                       pb 
                                                                         (n=20)                                 (n=17)                                                 
Energy (kcal)  Baseline  2065.0 ± 521.7  2018.6 ± 639.5    
   Week 12 1399.4 ± 441.3   1327.1 ± 336.0 
   Change  -665.6 ± 682.7 (<0.001) -691.5 ± 614.9 (<0.001) 0.905 
Fat calories (%)  Baseline  34.8 ± 6.7  39.8 ± 6.4 
   Week 12 29.9 ± 6.4  28.9 ± 7.1 
   Change  -4.9 ± 8.1 (0.013)  -10.9 ± 9.3 (<0.001) 0.044 
  
Carbohydrate calories (%) Baseline  47.6 ± 8.1  43.1 ± 8.0   
   Week 12 52.8 ± 8.1  53.8 ± 9.4 
   Change  5.2 ± 11.5 (0.056) 10.7 ± 10.9 (0.001) 0.147 
 
Protein calories (%) Baseline  17.02 ± 3.4  17.8 ± 3.0 
   Week 12 19.8 ± 3.5  19.3 ± 3.2 
    Change  2.8 ± 4.1 (0.006)  1.5 ± 4.7 (0.221)  0.351 
 
Total Fiber (mg/dl)    Baseline  17.3 ± 8.0  15.6 ± 6.7 
   Week 12 18.7 ± 8.6  18.4 ± 8.7 
   Change  1.3 ± 8.0 (0.466)  2.8 ± 6.7 (0.106)  0.560 
   
Note.  
Treatment group hypocaloric diet, exercise and dietary antioxidant supplement (LSANT) or hypocaloric diet, 
exercise and appetite suppression supplement (LSAS) 
ap-values for within-group change from baseline compared by paired samples t-test 
bp-values for between group mean changes compared by independent samples t-test 
 
 
Total energy consumed decreased significantly (p<0.001) at 12 weeks within both groups 
(LSANT: 2065 ± 522 kcal to 1399 ± 441 kcal; LSAS: 2018 ± 639 kcal to 1327 ± 336 kcal).  
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Percent calories from carbohydrate (LSANT: 53%; LSAS: 54%), fat (LSANT: 30%; LSAS: 
29%) and protein (LSANT: 20%; LS: 19%) were close to the amounts planned by week 12 in 
both groups (55%, 25% and 20% respectively).  There was a significant mean difference found 
between the groups for percent calories from fat (LSANT: -4.9 ± 8.1%; LSAS: -10.9 ± 9.3%, 
p=0.044). 
Dietary Antioxidant Intake 
As shown in Table 10, there were no significant changes (p>0.05) after 12 weeks in the intake of 
total fiber, vitamin E, total vitamin A, beta-carotene, alpha-carotene, beta-crypoxanthin, or 
lycopene within or between the groups.    
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Table 10. 
Dietary Antioxidants at Baseline and Week 12 
                                                                              
                                                                         LSANT                               LSAS                                                             
Measure                             Study Period          ± s.d. (P-value)a                 ± s.d. (P-value)a                          pb 
                                                                         (n=20)                                (n=17)                                                 
Vitamin E (mg)  Baseline  9.4 ± 7.9  9.6 ± 8.1     
   Week 12 7.6 ± 7.8   7.4 ± 5.4 
   Change  -1.7 ± 11.0 (0.496)             -2.1 ± 9.7 (0.382)  0.906 
Selenium (mcg)  Baseline  114.1 ± 32.7  118.2 ± 44.4 
   Week 12 91.8 ± 42.6  85.3 ± 31.9 
   Change  -22.3 ± 53.8 (0.080) -32.9 ± 40.6 (0.004) 0.509 
  
Total Vitamin A (mcg) Baseline  902.6 ± 823.4  1103.9 ± 789.3   
   Week 12 967.0 ± 488.5  1178.2 ± 561.2 
   Change  64.3 ± 997.1 (0.776) 74.3 ± 605.9 (0.620) 0.972 
 
Beta-Carotene (mcg) Baseline  2649.6 ± 4859.2  3051.2 ± 3400.6 
   Week 12 3446.4 ± 2416.4  4229.6 ± 2526.2 
    Change  796.8 ± 5275.8 (0.508) 1178.3 ± 2625.2 (0.083) 0.788 
 
Alpha-Carotene (mcg)    Baseline  230.6 ± 410.9  690.3 ± 1077.2 
   Week 12 674.9 ± 1028.4  1056.8 ± 979.2 
   Change  444.3 ± 1163.2 (0.104) 366.6 ± 926.4 (0.122) 0.826 
 
Beta-Cryptoxanthin (mcg) Baseline  271.9 ± 640.4  84.4 ± 85.3 
   Week 12 309.4 ± 773.5  255.1 ± 593.3 
   Change  37.6 ± 566.8 (0.770) 170.7 ± 593.5 (0.253) 0.490 
 
Lutein/zeaxanthin (mcg) Baseline  1960.2 ± 1551.1  1882.4 ± 1082.0 
   Week 12 3088.4 ± 2322.8  2420.9 ± 1873.4 
   Change  1128.1 ± 2222.0 (0.035) 538.5 ± 2199.4 (0.328) 0.424 
 
Lycopene (mcg)  Baseline  4629.9 ± 5691.2  5482.8 ± 5574.5 
   Week 12 3903.2 ± 2703.1  3956.0 ± 4245.8 
   Change  -726.7 ± 5698.9 (0.575) -1526.8 ± 6519.3 (0.349) 0.693 
Note.  
Treatment group hypocaloric diet, exercise and dietary antioxidant supplement (LSANT) or hypocaloric diet, 
exercise and appetite suppression supplement (LSAS) 
ap-values for within-group change from baseline compared by paired samples t-test 
bp-values for between group mean changes compared by independent samples t-test 
 
 
A significant decrease in selenium intake occurred in the LSAS group at week 12 (118.2 ± 44.4 
mcg and 85.3 ± 31.9 mcg p=0.004).  Lutein/zeaxanthin consumption was significantly increased 
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from baseline at week 12 for the LSANT group (1960.2 ± 1551.1 mcg and 3088.4 ± 2322.8 mcg, 
p=0.035) but not the LSAS group (p>0.05). 
Adverse Effects  
 
The most frequently reported symptom from the administration of HTP Complex®/Tēgreen® was 
nausea (18%, n=3).  Nausea was attributed to the administration of HTP Complex® and not to 
the administration of Tēgreen®.  Previous studies have reported nausea to be a side effect of 5-
HTP administration (Cangiano et al., 1992).  The dose of HTP Complex® was reduced to once a 
day until the nausea subsided.  Gradual increments in dose were achieved until in 2-3 weeks, the 
prescribed dose of three times a day was again taken.  Subjects taking LifePak® reported no 
adverse effects.   
Compliance 
 
Exercise 
Exercise compliance was determined by the exercise physiologist using clinic visit notes and the 
subject’s exercise logs.  Missing one exercise day a week was considered noncompliant.  
Overall, 86.5% (n=32) of the subjects were compliant with the exercise prescription.  
Compliance was 85% (n=17) in the LSANT group and 88% (n=15) in the LSAS group.  
Noncompliance was due to missing a day of the week as opposed to the amount of time needed 
to perform the physical activity.  Missing days were primarily due to illness, work, and travel in 
that order.  Based on improvements in the relative and absolute VO2max after 12 weeks, the data 
would indicate good compliance to this exercise prescription.  
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Diet 
Dietary compliance was determined by the dietitian using clinic visit notes and the subject’s diet 
records.  Subjects that failed to record or track > 25% of their diet entries every week were 
considered noncompliant.  Overall, 89% (n=33) of the subject’s were compliant in completing 
dietary study documents.  Compliance was 90% (n=18) in the LSANT group and 88% (n=15) in 
the LSAS group.  It should be noted that overall compliance should also be evaluated on the 
basis of the 3-day food record at week 12.  The percent calorie amounts for this study for 
subjects on the Exchange diet were set at 55% calories from carbohydrate, 25% calories from fat 
and 20% percent calories from protein.  At 12 weeks, the average percent calories for each group 
were (LSANT: 53%; LSAS: 54%) from carbohydrate, (LSANT: 30%; LSAS: 29%) from fat and 
(LSANT: 20%; LS: 19%) from protein.  This data would indicate that dietary compliance was 
good.   
Supplements 
Compliance in taking LifePak® was determined by the number of packets taken every week. 
Missing more than 2 packets a week was considered noncompliant.  Compliance was 90% 
(n=18) in the LSANT group.  The morning packet was the most often missed dose and the reason 
for missing it was forgetting to take it and then not having it available until later in the day.  
Compliance in taking HTP Complex®/Tēgreen® was determined by taking at least 2 of the 3 
doses of both HTP Complex® and Tēgreen® on a daily basis.  Compliance was 65% (n=11) in 
the LSAS group.  However, three of these subjects had an adverse affect as was noted above.  
The afternoon dose was frequently the dose missed in this group.  This was also due to not 
having the supplement with them when they ate lunch.   
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DISCUSSION 
 
The main purpose of this study was to determine the effects of a lifestyle modification 
program (hypocaloric diet and exercise) on weight and risk factors for the metabolic syndrome 
and CVD.  The secondary purpose was to determine the effect of dietary supplementation on 
weight loss and skin carotenoid levels.  Thirty-seven subjects were randomized into one of two 
groups (LSANT, n=20; LSAS, n=17).  At baseline, the only significant difference found between 
the groups was LDL-c (p=0.041).  This difference was attributed to the differences in total 
cholesterol found at baseline (LSANT: 205.3 ± 40.6 mg/dl and LSAS: 182.9 ± 28.5 mg/dl, 
p=0.06).   
The main findings of the present investigation are: 1) Lifestyle intervention that involves 
a structured hypocaloric diet and increased physical activity results in weight loss and 
improvements in body fat mass and waist circumference; 2) Supplementation with an appetite 
suppressant (HTP Complex®) does not enhance weight loss beyond what is achieved with a 
structured lifestyle intervention; 3) Antioxidant supplementation may be of benefit during a 
weight loss program that incorporates physical activity and a low energy diet; and 4) Overall 
compliance was high to the lifestyle intervention (exercise and hypocaloric diet). 
The decrease in morbidity and mortality associated with weight loss in overweight and 
obese individuals following lifestyle intervention programs has been well documented.  Results 
from the U.S. DPP and the FDPS as well as numerous other studies have reported that modest 
reductions in weight (5%) results in favorable changes in lipid concentrations, insulin resistance, 
blood pressure, waist circumference, percent body fat, and visceral adiposity (Anderson & Konz, 
2001; Dattilo & Kris-Etherton, 1992; Knowler et al., 2002; Lindstrom et al., 2006; MacMahon, 
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Cutler, Brittain, & Higgins, 1987; Selvin et al., 2007; Stewart et al., 2005; Tuomilehto et al., 
2001).  In the present investigation, a weight loss of 3.7% (LSANT) and 5.4% (LSAS) produced 
favorable changes in total body fat mass, percent body fat and waist circumference (Figure 3-4).   
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Figure 3. 
Mean Change in Weight 
*Different from baseline within the group p<0.05  
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Body Fat Mass Baseline to Week 12 
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Figure 4. 
Total Body Fat, Percent Body Fat, and Waist Circumference Baseline to Week 12 
* Different from baseline within the group p<0.05  
† Different between the groups p<0.05 
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In addition, a significant mean difference was found between the groups for body fat mass 
(Figure 5). 
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Figure 5. 
Mean Change in Body Fat Mass 
† Different between the groups p<0.05 
 
 
The difference found between the groups for body fat mass (LSANT: -1.8 kg vs. LSAS -3.4 kg) 
can be attributed to the difference in weight loss found in the groups (LSANT: -2.8 kg vs. LSAS 
-4.3 kg).  However, the dietary supplement Tēgreen® should also be considered.  Tēgreen® 
contains 97% polyphenols of which 65% are catechins.  Catechins have been found to play a role 
in the control of body composition via sympathetic activation of thermogenesis and/or fat 
oxidation (Dulloo et al., 1999; Dulloo et al., 2000).  Green tea extract has been found to increase 
24-hour energy expenditure by 4% due to its affect on stimulating brown adipose tissue 
thermogenesis (Dulloo et al., 1999).  Furthermore, green tea extract (containing catechins) taken 
for 3 months without dietary restriction decreased weight (4.6 %) and waist circumference 
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(4.5%) in overweight and obese adults (Chantre & Lairon, 2002).  Moreover, decreases in body 
fat were found in healthy young men that consumed green tea (690 mg catechins) for 12 weeks 
(Nagao et al., 2005).  Therefore, although the difference found in body fat mass is most likely 
due to the amount of weight lost in each group, the effect of Tēgreen® cannot be ruled out.  
Green tea has also been found to improve insulin sensitivity and regulate blood glucose 
(McKay & Blumberg, 2002; S. Wolfram, Wang, & Thielecke, 2006; Wu et al., 2003).  We found 
decreased glucose and insulin levels and improvements in insulin resistance in the LSAS group 
but not the LSANT group (Figure 6).   
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Figure 6. 
Glucose, Insulin and HOMA-IR Baseline to Week 12 
* Different from baseline p<0.05 
† Different between the groups p<0.05 
 38
Furthermore, a significant mean difference was found between the groups for glucose (Figure 7).   
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Figure 7. 
Mean Change in Glucose 
* Different between the groups p<0.05 
 
 
Weight loss and decreases in body fat mass, specifically visceral fat, have been shown to 
improve insulin resistance (Knowler et al., 2002; Lindstrom et al., 2006).  The improvements 
found in glucose, insulin and insulin resistance in the LSAS group were most likely due to the 
differences in body fat mass (LSAS: 9.4%; LSANT: 5.3%) and weight loss (LSAS: >5%; 
LSANT: <5%).  However, factors other than weight loss may be considered.  As first noted 
above, green tea has been shown to improve glucose tolerance and insulin sensitivity (S. 
Wolfram et al., 2006).  This is thought to be due to the action of the catechins in the green tea.   
Currently under investigation, it is thought that the catechins increase the basal and insulin 
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stimulated glucose uptake in the adipocytes in addition to the rehabilitation of damaged beta-
cells.  In addition, epigallocatechin gallate (EGCG), a bioactive polyphenol in green tea, has 
been shown to mimic the metabolic actions of insulin to inhibit gluconeogenesis in hepatocytes 
(Kao, Chang, Lee, & Chen, 2006).  Until recently, the majority of research on green teas effects 
has been done in the laboratory on animals and most human studies on green tea consumption 
have been epidemiological in nature.  Further research is needed to determine what role green tea 
has in reducing obesity and the risk factors associated with the metabolic syndrome in humans.   
Dyslipidemias are a common characteristic of the MS and CVD.  Results from weight 
loss lifestyle studies show varying levels of change in total cholesterol, HDL-c, LDL-c, and 
triglyceride concentrations depending on the lifestyle intervention used (diet, exercise, or 
combination of diet and exercise) and the extent of the dyslipidemia present in the population 
studied.  The mean values found for cholesterol, triglycerides, HDL-c, and LDL-c at baseline in 
our subjects were normal.  There were no significant effects on total cholesterol, triglycerides, or 
LDL-c following 12 weeks of lifestyle intervention (low energy diet and physical activity).  A 
significant, but modest decrease was found in HDL-c in the LSANT group.  Lifestyle 
intervention studies involving women have shown decreases in HDL-c following weight loss 
(Anderson, Brinkman-Kaplan, Lee, & Wood, 1994; Dattilo & Kris-Etherton, 1992; Thompson, 
Jeffery, Wing, & Wood, 1979).  Furthermore, data from other studies suggest that the decrease in 
HDL-c that occur with active weight loss is reversed during subsequent periods of weight 
maintenance (Dattilo & Kris-Etherton, 1992).   
Lifestyle intervention (hypocaloric diet and exercise) is considered the first line of 
treatment to reduce the risk factors for the MS and CVD.  As previously shown (Figure 1), a 
number of factors are involved in regulating appetite.  A number of experimental data support 
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the role played by serotonin in the regulation of feeding behavior.  Decreased levels of serotonin 
have been found in the central nervous system of dieters which has been associated with 
carbohydrate cravings and binge eating in obese individuals (Ceci et al., 1989).  5-
Hydroxytryptophan (5-HTP) is the immediate precursor to serotonin.  HTP Complex® contains 
150 mg of 5-HTP per capsule.  Subjects were instructed to take 300 mg of 5-HTP three times a 
day.  This dose is equivalent to the dosage used in previous weight loss studies using 5-HTP.  In 
the present study, HTP Complex® in combination with a calorie restricted diet and physical 
activity did not significantly increase weight loss more than low energy diet and physical activity 
alone (Figure 8).   
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Figure 8. 
Mean Change in Weight 
p>0.05 
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However, although statistical significance was not found between the groups, we did find a trend 
toward more weight loss in the LSAS group.  Sample size in addition to poor compliance (65%) 
in taking the dietary appetite supplement may account for the lack of statistical significance 
found.  Several studies have found weight loss following administration of 5-HTP in 
combination with and without diet restriction in overweight an obese women (Cangiano et al., 
1991; Cangiano et al., 1992; Ceci et al., 1989).  In a double-blind, placebo-controlled study with 
subjects taking 300 mg 5-HTP three times a day or placebo, weight loss in addition to a 
spontaneous reduction in energy intake (3220 to 1879 kcal) and carbohydrate intake (50%) was 
noted in the 5-HTP group (Cangiano et al., 1992).  These results occurred during the first six 
weeks of the study during which no caloric restriction was prescribed.  It was suggested that the 
results were due to the administration of 5-HTP which decreased the subjects carbohydrate 
cravings and binge eating.  However, as many as 80% of the subjects initially reported nausea 
and/or vomiting.  This suggests that the reductions in energy intake found during the first 6 
weeks of the study may have been due to the adverse effects (nausea and vomiting) associated 
with 5-HTP administration.  The results of this study also indicate that nausea may be a problem 
with 5-HTP at this dose.  It is possible that lower doses of 5-HTP may be effective in reducing 
body weight.  However, more time may be needed to achieve this result.  The administration of 
lower doses of 5-HTP in combination with and without caloric restriction have not been studied 
to our knowledge.    
Weight loss programs typically reduce dietary energy consumption and vary the 
percentages of carbohydrates, fats and proteins which can create nutritionally unbalanced diets.  
In addition, lower fruit and vegetable consumption (and presumably antioxidant intake) has been 
found in overweight and obese individuals as compared to their leaner counterparts (Bialostosky, 
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2002; Fairfield & Fletcher, 2002; Tapiero et al., 2004).  These diets are often poor in 
micronutrients thereby increasing the risk for chronic disease.  Furthermore, carotenoid levels in 
serum and skin have been found to be lower in individuals with higher BMI and adiposity 
(Andersen et al., 2006; Brady et al., 1996; Fiutem J, 2004; Moor de Burgos et al., 1992).  In the 
present study, skin carotenoid scores at baseline were 18,000 to 20,000 (Figure 9).   
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Figure 9. 
Skin Carotenid Scores Baseline to Week 12 
* Different from baseline within the group p<0.05  
† Different between the groups p<0.05 
 
 
Twelve weeks of supplementation with a dietary antioxidant containing significant amounts of 
antioxidants, vitamins, and minerals (LSANT group) resulted in a significant increase in skin 
carotenoid scores (Figure 9).  Previous research in our lab found that following 24 weeks of a 
well designed program of caloric restriction and physical activity, skin carotenoid scores 
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decreased significantly with weight loss (Zukley L, 2004).  Subjects were instructed not to take 
any dietary supplements (over-the-counter or prescribed) for the duration of the study.  In the 
current study however, the LSAS group was instructed to take Tēgreen®.  Tēgreen® contains 
large amounts of polyphenols, and to a lesser extent carotenoids, tocopherols, vitamin C, as well 
as the minerals manganese, chromium, selenium, and zinc and other phytochemicals which have 
strong antioxidant activity.  These additional compounds could account for the slight increase we 
found in the skin carotenoid score.  Limited research is available on the effects of weight loss on 
antioxidant status in overweight and obese individuals.  Studies have investigated antioxidant 
status following weight loss associated with bariatric surgery.  However, the applicability of this 
data to the general population is limited.   
Dietary compliance was found to be good in our subjects based on the completion of diet 
records.  In addition, the fact that both groups closely obtained the recommended percent levels 
of carbohydrates, fats and proteins (55%, 25% and 20% respectively) at week 12 suggests good 
dietary compliance in these subjects.  Furthermore, mean average intake as determined by the 3-
day food records at week 12 indicate an energy reduction of 650-700 kcal/day.  However, this 
reduction in energy intake would indicate that on average, a weight loss of 12 pounds (5.4 kg) 
would occur.  Subjects in the LSANT group lost on average 6.2 pounds (-2.8 kg) and the LSAS 
group lost on average 9.5 pounds (-4.3 kg) after 12 weeks.  Our results suggest that subjects may 
have under reported nutritional intake.  Research from numerous studies indicates that women 
and higher BMI status is representative of under reporters compared to those individuals that 
accurately report their dietary intake (Bailey, Mitchell, Miller, & Smiciklas-Wright, 2007; 
Huang, Roberts, Howarth, & McCrory, 2005; Voss, Kroke, Klipstein-Grobusch, & Boeing, 
1998).  Furthermore, foods that are deemed unhealthy are usually underreported by subjects and 
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may account for as much as a 10-50% difference in energy intake a day (Huang et al., 2005; 
McCrory, McCrory, Hajduk, & Roberts, 2002).  Therefore, although compliance in completing 
diet records was high, the data suggest that underreporting of nutritional intake on the 3-day food 
record occurred.  
Micronutrient intake was found to be similar between the groups.  However, the dietary 
intake of selenium was significantly lower in the LSAS group at week 12.  Selenium deficiency 
is rare in the U. S. due to high selenium soil levels and the fact that food is distributed from 
geographic regions around the country.  Furthermore, despite the decrease in dietary selenium 
intake, the levels were still above the recommended intake of 55 μg.  The decrease in intake is 
most likely a result of transient dietary changes (decreased consumption of meat and seafood).  
The increase in lutein/zeaxanthin that was found in the LSANT group at 12 weeks may be due to 
the increased consumption of fruits and especially dark green vegetables and the concomitant use 
of dietary supplements containing beta-carotene.  Currently, there is no recommended dietary 
intake for this carotenoid and there are no reported cases of over dosage.    
A limitation of this study was sample size. This cohort of subjects taken from the larger 
intervention study was not powered to find differences between the groups.  In addition, 
compliance to the dietary appetite suppressant was low.  This suggests that significant 
differences may have been found between the groups had compliance been higher.  
Recommendations for future research involve the evaluation of how chronic dieting and weight 
loss affect overall antioxidant status.  In addition, due to the increasing prevalence of obesity and 
obesity related complications and the conflicting reports found with weight loss on skin 
carotenoid levels, further research is necessary to determine the effect of weight loss on 
antioxidant levels. 
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CONCLUSION 
 
In conclusion, we examined the effects of a lifestyle intervention program (low energy 
diet and physical activity) on weight loss and risk factors for the MS and CVD.  We also looked 
at the effect of dietary supplementation on weight loss and skin carotenoid levels.  A hypocaloric 
diet in combination with physical activity resulted in weight loss and improvements in waist 
circumference, body fat mass, and percent body fat.  Furthermore, weight loss in combination 
with losses in body fat mass resulted in additional improvements in glucose, insulin and insulin 
resistance.  This suggests that fat mass loss in combination with weight loss is an important 
factor in risk reduction for the MS and CVD.  Additionally, due to the health benefits associated 
with green tea, green tea consumption in conjunction with lifestyle intervention changes may 
provide additional health benefit.  The addition of an appetite suppressant (HTP Complex®) did 
not enhance weight loss beyond that of the lifestyle intervention alone, although there was a 
trend toward increasing weight loss.  Furthermore, weight loss was not shown to adversely affect 
skin carotenoid scores.  The addition of green tea however, which contains small amounts of 
carotenoid antioxidants may be responsible for these results.   
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